

Ellen L Weisberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5114721/publications.pdf>

Version: 2024-02-01

74
papers

5,754
citations

172457

29
h-index

91884

69
g-index

75
all docs

75
docs citations

75
times ranked

6465
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. <i>Cancer Cell</i> , 2005, 7, 129-141.	16.8	1,387
2	Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. <i>Cancer Cell</i> , 2002, 1, 433-443.	16.8	574
3	Smad4 and FAST-1 in the assembly of activin-responsive factor. <i>Nature</i> , 1997, 389, 85-89.	27.8	534
4	Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL ⁺ transformed hematopoietic cell lines. <i>Blood</i> , 2000, 95, 3498-3505.	1.4	374
5	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degradator. <i>Cell Chemical Biology</i> , 2018, 25, 88-99.e6.	5.2	313
6	ARG tyrosine kinase activity is inhibited by STI571. <i>Blood</i> , 2001, 97, 2440-2448.	1.4	246
7	PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR [±] -induced myeloproliferative disease. <i>Cancer Cell</i> , 2003, 3, 459-469.	16.8	223
8	Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. <i>Cell Chemical Biology</i> , 2017, 24, 1490-1500.e11.	5.2	149
9	Tensin: A potential link between the cytoskeleton and signal transduction. <i>BioEssays</i> , 1994, 16, 817-823.	2.5	125
10	Repurposing of Kinase Inhibitors for Treatment of COVID-19. <i>Pharmaceutical Research</i> , 2020, 37, 167.	3.5	102
11	Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL ⁺ leukemias. <i>Blood</i> , 2007, 109, 2112-2120.	1.4	98
12	FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. <i>Drug Resistance Updates</i> , 2009, 12, 81-89.	14.4	95
13	Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity. <i>Gastroenterology</i> , 2006, 131, 1734-1742.	1.3	93
14	Inhibition of USP10 induces degradation of oncogenic FLT3. <i>Nature Chemical Biology</i> , 2017, 13, 1207-1215.	8.0	89
15	Resistance to imatinib (Glivec): update on clinical mechanisms. <i>Drug Resistance Updates</i> , 2003, 6, 231-238.	14.4	84
16	Potential of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL ⁺ and mutant FLT3-expressing cells. <i>Blood</i> , 2008, 111, 3723-3734.	1.4	81
17	Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. <i>Blood</i> , 2004, 104, 1855-1858.	1.4	80
18	Potential of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1951-1961.	4.1	78

#	ARTICLE	IF	CITATIONS
19	Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. <i>Scientific Reports</i> , 2020, 10, 5324.	3.3	69
20	Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1121-1129.	4.1	65
21	Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR β , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. <i>Blood</i> , 2010, 115, 4206-4216.	1.4	61
22	Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2249-2259.	4.1	53
23	Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies. <i>Leukemia</i> , 2015, 29, 27-37.	7.2	51
24	Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells. <i>PLoS ONE</i> , 2011, 6, e25351.	2.5	42
25	Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. <i>Oncotarget</i> , 2016, 7, 69760-69769.	1.8	41
26	Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells. <i>PLoS ONE</i> , 2013, 8, e56473.	2.5	38
27	Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells. <i>Oncotarget</i> , 2015, 6, 31313-31322.	1.8	38
28	Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. <i>Genes and Cancer</i> , 2010, 1, 1021-1032.	1.9	33
29	Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. <i>British Journal of Haematology</i> , 2019, 187, 488-501.	2.5	30
30	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. <i>Blood</i> , 2008, 112, 5161-5170.	1.4	29
31	Structure-guided development of covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 838-846.	3.0	28
32	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. <i>Oncotarget</i> , 2017, 8, 67639-67650.	1.8	26
33	Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. <i>Blood</i> , 2015, 125, 3133-3143.	1.4	23
34	Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML. <i>Oncotarget</i> , 2016, 7, 29131-29142.	1.8	21
35	Discovery of (4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 875-892.	6.4	20
36	Inhibition of the deubiquitinase USP10 induces degradation of SYK. <i>British Journal of Cancer</i> , 2020, 122, 1175-1184.	6.4	19

#	ARTICLE	IF	CITATIONS
37	Simultaneous inhibition of Vps34 kinase would enhance PI3K γ inhibitor cytotoxicity in the B-cell malignancies. <i>Oncotarget</i> , 2016, 7, 53515-53525.	1.8	19
38	Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. <i>Oncotarget</i> , 2017, 8, 52026-52044.	1.8	19
39	Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition. <i>Oncotarget</i> , 2017, 8, 109973-109984.	1.8	19
40	Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 476-481.	2.8	17
41	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 1320-1328.	3.0	17
42	A non-covalent inhibitor XMU μ MP β overrides ibrutinib-resistant <i>Btk</i> ^{C481S} mutation in B-cell malignancies. <i>British Journal of Pharmacology</i> , 2019, 176, 4491-4509.	5.4	17
43	Upregulation of IGF1R by Mutant <i>RAS</i> in Leukemia and Potentiation of <i>RAS</i> Signaling Inhibitors by Small-Molecule Inhibition of IGF1R. <i>Clinical Cancer Research</i> , 2014, 20, 5483-5495.	7.0	16
44	Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 137, 545-557.	5.5	16
45	Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2968-2980.	3.6	16
46	Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2468-2477.	4.1	15
47	Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1299-1308.	0.8	15
48	Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 175-182.	2.0	15
49	Midostaurin, a Natural Product-Derived Kinase Inhibitor Recently Approved for the Treatment of Hematological Malignancies. <i>Biochemistry</i> , 2018, 57, 477-478.	2.5	15
50	Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). <i>Cancers</i> , 2021, 13, 7.	3.7	13
51	An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFR α and kit. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4579-4584.	2.2	12
52	Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2. <i>Leukemia</i> , 2022, 36, 210-220.	7.2	12
53	BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	11
54	Development of α -DFG-out TM inhibitors of gatekeeper mutant kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5297-5302.	2.2	10

#	ARTICLE	IF	CITATIONS
55	Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. <i>Leukemia</i> , 2020, 34, 625-629.	7.2	9
56	Simultaneous Administration of AMN107 and Imatinib in the Treatment of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 694-694.	1.4	7
57	Characterization of selective and potent PI3K \hat{I} inhibitor (PI3KD-IN-015) for B-Cell malignancies. <i>Oncotarget</i> , 2016, 7, 32641-32651.	1.8	7
58	Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. <i>Archives of Toxicology</i> , 2014, 88, 2233-2242.	4.2	6
59	Current therapies under investigation for COVID-19: potential COVID-19 treatments. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 483-489.	1.4	6
60	Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 334.	17.1	6
61	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-9.	1.3	5
62	Inhibition of the \hat{A} ubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2. <i>Leukemia</i> , 2022, 36, 1048-1057.	7.2	5
63	Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). <i>British Journal of Cancer</i> , 2021, 125, 582-592.	6.4	4
64	Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 605-609.	3.5	3
65	The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2145-2156.	3.6	2
66	AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.. <i>Blood</i> , 2004, 104, 551-551.	1.4	2
67	Small Molecule Activators Of AMPK Block The Glycogen Production Required For Transformation Of Myeloid Leukemia Cells. <i>Blood</i> , 2013, 122, 1479-1479.	1.4	2
68	HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance. <i>Blood Science</i> , 2021, 3, 151-153.	0.9	1
69	Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. <i>Blood</i> , 2005, 106, 1578-1578.	1.4	1
70	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. <i>Blood</i> , 2009, 114, 1722-1722.	1.4	0
71	Potential of the Effects of Nilotinib by Combination with Plerixafor in a Mouse Model of BCR-ABL-Positive Residual Disease. <i>Blood</i> , 2011, 118, 2737-2737.	1.4	0
72	BCR-ABL Transformation Requires Glycogen Synthase 1 (GYS1) Expression for Cell Growth and Increased Glycogen Production. <i>Blood</i> , 2012, 120, 1673-1673.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Integrin-Linked Kinase a Novel Therapeutic Target for Acute and Chronic Myeloid Leukemia. Blood, 2015, 126, 3694-3694.	1.4	0
74	Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia. Blood, 2016, 128, 524-524.	1.4	0